Ann: Nuheara Clinical Trial and FDA 510(K) Pathway Update, page-29

The various investor presos we've seen imply that Pro will target severe hearing loss and will be comparable with traditional hearing aids in terms of the hearing loss remediated. I'm expecting Pro to be a significant step change over Max, and the recent trials and other FDA compliance and approval processes indicate Pro will be a fully fledged hearing aid and categorised as such by the FDA. Whether they retail for US$1500 remains to be seen, but I think we're definitely looking at over US$1000 as the entry point for Pro.